LPOXY Therapeutics is working to solve a $6 billion healthcare problem with no approved preventive solutions available.
Patients – Half a million Americans will get antibiotic-induced C. difficile colitis this year and 30,000 will die
Current Preventive Options – No approved therapies currently for the prevention of primary infections
Annual US Healthcare Cost of C. difficile – $6+ billion
Public Health Status – CDC designated urgent public health threat
Therapy Targeting Strategy – Co-administered with high-risk antibiotics
Therapy Course Frequency – Repeatable with each high-risk antibiotic exposure
Our patented therapy, SIDIPREV™, is moving towards pivotal clinical trial in 2026.
With successful clinical validation, SIDIPREV™ could become the new standard of care for C. difficile prevention — delivering high clinical impact to address this unmet need.
Hospitals face substantial financial penalties and unreimbursed costs from C. difficile infections. SIDIPREV™ offers cost-efficiency for hospitals — significantly reducing infection-related losses.
With no vaccine hesitancy, no antimicrobial stewardship barriers, and no competing prevention therapies, SIDIPREV™ is uniquely positioned for rapid adoption and scalable market penetration.
Clinical & Regulatory Asset Acquisition
In 2025, LPOXY acquired clinical and regulatory assets that reduce development risk and accelerate initiation of the SIDIPREV™ registrational trial for C. difficile prevention.
Robust Intellectual Property Protection
SIDIPREV™ is protected by a portfolio of issued patents in major global markets, securing long-term exclusivity and market value.
Efficient Development Pathway
LPOXY plans to initiate a registrational trial for SIDIPREV™ for the prevention of C. difficile colitis in at-risk patients taking antibiotics in 2026.
C. difficile has been identified by the Centers for Disease Control and Prevention (CDC) as an urgent public health threat, contributing to more than 80 American deaths each day.
SIDIPREV’s development strategy builds on existing human safety data and extensive clinical precedent for intestinal oxygen exposure, reducing development risk and uncertainty.
Capital Raise: Pivotal Trial Execution
LPOXY is raising capital to execute our registrational clinical trial.
We are assembling a syndicate of strategic investors to enable trial initiation in 2026 and drive value-creation milestones through NDA submission.